Profile data is unavailable for this security.
About the company
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
- Revenue in PLN (TTM)337.26m
- Net income in PLN65.30m
- Incorporated2019
- Employees387.00
- LocationSelvita SAHexagon, Ul. Podole 79KRAKOW 30-394PolandPOL
- Phone+48 123005001
- Fax+48 122974701
- Websitehttps://selvita.com/
Mergers & acquisitions
| Acquired company | SLV:WSE since announced | Transaction value |
|---|---|---|
| PozLab Sp z o o | 2.78% | 6.29m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecure SA | 360.18k | -21.91m | 235.37m | 112.00 | -- | 2.50 | -- | 653.47 | -1.35 | -1.35 | 0.0223 | 5.59 | 0.003 | -- | 0.0741 | 3,244.87 | -18.17 | 2.64 | -19.29 | 2.76 | -444.01 | 97.54 | -6,082.40 | 12.84 | -- | -- | 0.0657 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Poltreg SA | 600.00k | -17.42m | 254.62m | 23.00 | -- | 3.21 | -- | 424.37 | -3.74 | -3.74 | 0.1287 | 17.04 | 0.0051 | 27.12 | 3.22 | 26,373.63 | -14.82 | -6.51 | -16.41 | -7.35 | -1,804.83 | -391.38 | -2,903.50 | -449.24 | 4.21 | -- | 0.0913 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Mabion SA | 139.86m | 37.39m | 270.88m | 226.00 | 7.25 | 1.86 | 5.88 | 1.94 | 2.31 | 2.31 | 8.65 | 9.01 | 0.7538 | 4.02 | 17.35 | 618,836.30 | 20.15 | -7.19 | 25.09 | -16.79 | 78.30 | 58.10 | 26.73 | -14.27 | 1.64 | 101.63 | 0.026 | -- | -7.50 | -- | 77.94 | -- | 40.86 | -- |
| BIOTON SA | 186.32m | -6.85m | 290.22m | 358.00 | -- | 0.4849 | 11.26 | 1.56 | -0.0797 | -0.0797 | 2.17 | 6.97 | 0.2303 | 1.02 | 21.19 | 520,435.80 | -0.8464 | -1.99 | -1.04 | -2.47 | 33.80 | 45.33 | -3.67 | -8.61 | 0.2085 | 0.3295 | 0.0864 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Captor Therapeutics SA | 18.64m | -46.69m | 345.98m | 104.00 | -- | 6.83 | -- | 18.56 | -10.29 | -10.29 | 4.08 | 10.87 | 0.2391 | -- | 5.26 | 179,230.80 | -59.88 | -- | -83.65 | -- | 51.97 | -- | -250.46 | -- | -- | -- | 0.1114 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| Scope Fluidics SA | 93.00k | -22.60m | 447.05m | 40.00 | -- | 6.03 | -- | 4,807.02 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Selvita SA | 337.26m | 65.30m | 1.15bn | 387.00 | 17.68 | 3.53 | 10.24 | 3.42 | 3.56 | 3.56 | 18.37 | 17.83 | 0.553 | 9.29 | 4.70 | 398,178.30 | 10.71 | -- | 12.99 | -- | 79.66 | -- | 19.36 | -- | 1.41 | 11.34 | 0.4063 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
| Ryvu Therapeutics SA | 60.59m | -95.83m | 1.25bn | 230.00 | -- | 6.09 | -- | 20.64 | -4.15 | -4.15 | 2.63 | 8.88 | 0.1457 | 9.02 | 5.97 | 263,439.10 | -23.04 | -21.88 | -28.01 | -25.20 | 64.77 | -6.28 | -158.15 | -284.20 | 3.29 | -- | 0.29 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Allianz Polska PTE SAas of 29 Dec 2023 | 823.92k | 4.49% |
| Allianz Polska TFI SAas of 31 Dec 2023 | 394.26k | 2.15% |
| Vienna PTE SA Vienna Insurance Groupas of 31 Dec 2023 | 342.26k | 1.87% |
| Generali PTE SAas of 29 Dec 2023 | 325.18k | 1.77% |
| Investors TFI SAas of 31 Dec 2022 | 271.75k | 1.48% |
| PKO TFI SAas of 31 Jul 2024 | 170.21k | 0.93% |
| Pekao TFI SAas of 31 Dec 2023 | 140.99k | 0.77% |
| TFI PZU SAas of 30 Jun 2023 | 131.70k | 0.72% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 31 Dec 2023 | 113.68k | 0.62% |
| Millennium TFI SAas of 31 Dec 2023 | 29.56k | 0.16% |
